SecBot SecBot

XLO

Xilio Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001840233 Biotech & Drug Discovery
$7.41 +0.10 (+1.37%)
Oct 27 4:00 PM ET · prev $7.31
Market cap
$49.8M
Nano cap
Consensus
Buy
80% Buy or better · 5 analysts
Median target
$18.00
+143% · range $16.00–20.00
1 year
−36.3%
from $11.63 · Oct 27
30 days
−18.1%
from $9.05
52-week range
$7.14–11.90
−38% from high · low Mar 13
Avg volume 20D
14.4K
Oct 21 spike 36.3K
Short interest
🔒 Subscribers only
Insider net
+$2.0M
2 buyers · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
8
analyzed by SecBot
SecBot read BULLISH 3 reports · 90 days
Balance 0 bearish · 2 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 3/3
Strongest NEUTRAL Xilio Therapeutics announced dosing of the first patient in a Phase 1/2 trial of XTX501, a PD-1/masked IL-2…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    2 insiders bought $2.0M. No open-market sales.

  • InstitutionsMIXED

    Q2 2026: 2 added (0 new), 1 trimmed or exited.

  • AnalystsBULLISH

    4 of 5 rate it Buy or better. Every target is above the price.

  • EstimatesFLAT

    Current-quarter EPS estimate −$0.920 → −$0.935 over 90 days. 1 up, 0 down in 30 days.

  • TrendDOWNTREND

    17% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
VANGUARD CAPITAL MANAGEMENT LLCADD178,517$1.7M
RENAISSANCE TECHNOLOGIES LLCADD64,153$614.6K
UBS Group AGNEAR_EXIT14$134.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

5 analysts
Buy 80% rate it Buy or better
Strong Buy2Buy2Hold1Sell0Strong Sell0
12-month targets · 2 analysts

Price is below the lowest target. Median implies +143%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Oct 21, 2026Raymond James
INITIATE
INITIATEOutperform
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 26, 2026
FDA
Xilio Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of XTX501 in Patients with Metastatic NSCLC
XTX501 is a novel PD-1/masked IL-2 bispecific that has the potential to become a foundational backbone regimen for solid tumors
Oct 2, 2026
Press release
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and…
Sep 28, 2026
Press release
Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer
Dr. Houvras brings over two decades of executive leadership across premier industry and academic research institutions in clinical development…
Sep 2, 2026
Press release
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and…
Aug 12, 2026
Earnings
Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates
Received FDA clearance of IND application for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2

Insider ledger

Form 4
$2.0M
bought · 2 insiders
$0
sold · 0 insiders
DateInsiderTypeValue
Oct 1, 2026
Houvras Yariv
CHIEF MEDICAL OFFICER
AWARD105,000 sh
Jun 11, 2026
Curran Daniel J.
Director
AWARD5,000 sh
Jun 11, 2026
Bello Akintunde Olatokumbo
Director
AWARD5,000 sh
Jun 11, 2026
ROSS ROBERT W.
Director
AWARD5,000 sh
Jun 11, 2026
Bonstein Sara
Director
AWARD5,000 sh
Jun 11, 2026
Xu Yuan
Director
AWARD5,000 sh
Jun 11, 2026
Shannon James Samuel
Director
AWARD5,000 sh
Jun 11, 2026
Brennan Aoife
Director
AWARD5,000 sh

Earnings setup

Estimates
−$0.94
EPS estimate, this quarter
−2%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.94-$1.05–-$0.82-14.0%$4.9M
Next Q-$0.97-$1.10–-$0.85-14.7%$4.1M
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 26, 2026 Press
Xilio Therapeutics announced dosing of the first patient in a Phase 1/2 trial of XTX501, a PD-1/masked IL-2…
Impact 4/10
Oct 26, 2026 FDA
Xilio Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of XTX501 in Patients with Metastatic NSCLC
XTX501 is a novel PD-1/masked IL-2 bispecific that has the potential to become a foundational backbo
Oct 1, 2026 Insider
Houvras Yariv was granted 105,000 shares
CHIEF MEDICAL OFFICER
Aug 12, 2026 SEC
Xilio Therapeutics reported Q2 2026 results with collaboration revenue of $18.7M (up 131% YoY) and a net loss of $6.4M…
8-K — Impact 7/10
Aug 12, 2026 SEC
Xilio Therapeutics reported Q2 2026 collaboration revenue of $18.7M (up 131% YoY) and a net loss of $6.4M (improved…
PRESS-RELEASE — Impact 7/10
Jun 30, 2026 Inst.
VANGUARD CAPITAL MANAGEMENT LLC — ADD
178,517 shares ($1.7M)
Jun 30, 2026 Inst.
RENAISSANCE TECHNOLOGIES LLC — ADD
64,153 shares ($614.6K)
Jun 11, 2026 Insider
Curran Daniel J. was granted 5,000 shares
Director

SecBot reports

8 filings · 4 press releases · 3 bullish · 1 bearish · 4 neutral
All XLO filing & press-release reports (12)